Stage III Grade 3 Follicular Lymphoma Recruiting Phase 1 / 2 Trials for Rituximab (DB00073)
Indication | Status | Phase |
---|---|---|
DBCOND0028630 (Stage III Grade 3 Follicular Lymphoma) | Recruiting | 1 / 2 |
clinicaltrials.gov Identifier | Title | Purpose | Drugs |
---|---|---|---|
NCT02213913 | Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas | Treatment | |
NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | Treatment |